Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

Item
http://www.wikidata.org/entity/Q37594993
Efficacy of Dasatinib in a CML Patient in Blast Crisis with F317L Mutation: A Case Report and Literature ReviewNCI First International Workshop on the Biology, Prevention, and Treatment of Relapse after Allogeneic Hematopoietic Stem Cell Transplantation: Report from the Committee on Treatment of Relapse after Allogeneic Hematopoietic Stem Cell TransplantatioPhase I trial of maintenance sorafenib after allogeneic hematopoietic stem cell transplantation for fms-like tyrosine kinase 3 internal tandem duplication acute myeloid leukemia.Extramedullary blast crisis of chronic myelogenous leukemia as an initial presentationImmunological effects of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or philadelphia chromosome-positive acute lymphoblastic leukemiaRole of allo-SCT for CML in 2010.Activity and safety of dasatinib as second-line treatment or in newly diagnosed chronic phase chronic myeloid leukemia patients.Management of chronic myeloid leukemia in childhood.Management of advanced-phase chronic myeloid leukemia.Transplant to treatment-free remission: the evolving view of 'cure' in chronic myeloid leukemia.New drugs and allogeneic hematopoietic stem cell transplantation for hematological malignancies: do they have a role in bridging, consolidating or conditioning transplantation treatment?Allogeneic stem cell transplantation for chronic myeloid leukemia resistant to tyrosine kinase inhibitors.Dasatinib and Azacitidine Followed by Haploidentical Stem Cell Transplant for Chronic Myeloid Leukemia with Evolving Myelodysplasia: A Case Report and Review of Treatment Options.BCR-ABL Mutation-Guided Therapy for CML Blast Crisis: A Case Report.Outcome of allogeneic SCT in patients with chronic myeloid leukemia in the era of tyrosine kinase inhibitor therapy.Managing children with chronic myeloid leukaemia (CML): recommendations for the management of CML in children and young people up to the age of 18 years.Phase 1/2 study of nilotinib prophylaxis after allogeneic stem cell transplantation in patients with advanced chronic myeloid leukemia or Philadelphia chromosome-positive acute lymphoblastic leukemia.
P2860

Current status and perspectives of tyrosine kinase inhibitor treatment in the posttransplant period in patients with chronic myelogenous leukemia (CML).

Item
http://www.wikidata.org/entity/Q37594993
description
article científic
@ca
article scientifique
@fr
articolo scientifico
@it
artigo científico
@pt
bilimsel makale
@tr
scientific article published on 08 September 2009
@en
vedecký článok
@sk
vetenskaplig artikel
@sv
videnskabelig artikel
@da
vědecký článek
@cs
name
Current status and perspective ...... ic myelogenous leukemia (CML).
@en
Current status and perspective ...... h chronic myelogenous leukemia
@nl
type
label
Current status and perspective ...... ic myelogenous leukemia (CML).
@en
Current status and perspective ...... h chronic myelogenous leukemia
@nl
prefLabel
Current status and perspective ...... ic myelogenous leukemia (CML).
@en
Current status and perspective ...... h chronic myelogenous leukemia
@nl
P1433
P1476
P2093
P304
P31
P356
P433
P478
P50
P577
P5875
P698
P921
P356
P1433
P1476
Current status and perspective ...... ic myelogenous leukemia (CML).
@en
P2093
P304
P31
P356
10.1016/J.BBMT.2009.08.019
P433
P478
P50
P577
P5875
P698
P921